Evommune reprices Janice Suzann Drew’s stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. (EVMN) Chief of Dev. Operations Janice Suzann Drew reported an option repricing on November 13, 2026. Options covering 231,274 shares at an original $16 exercise price and 73,892 shares at an original $26.77 exercise price were deemed canceled and replaced with options covering the same respective share amounts at a $7.63 exercise price.
If exercised before the earliest of November 13, 2027, a Change in Control, or specified death, disability or employment events, the premium exercise price equals the original exercise price. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to buy) F1, F2, F3 | 231,274 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F1, F2, F3 | 231,274 | -- | -- |
| Disposition | Stock Option (Right to buy) F4, F2, F5 | 73,892 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F4, F2, F5 | 73,892 | -- | -- |
Footnotes (5)
- F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
- F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
- F3. One fourth (1/4) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
- F5. One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Key Terms
one-time stock option repricing technical
Change in Control technical
continuous service technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the EVMN option repricing terms for Janice Suzann Drew?
What are Janice Suzann Drew's EVMN option vesting terms?
AI-generated analysis. How Rhea-AI works. Not financial advice.